Results 21 to 30 of about 15,173,912 (274)

Liver-heart cross-talk mediated by coagulation factor XI protects against heart failure

Science, 2022
Tissue-tissue communication by endocrine factors is a vital mechanism for physiologic homeostasis. A systems genetics analysis of transcriptomic and functional data from a cohort of diverse, inbred strains of mice predicted that coagulation factor XI ...
Yang Cao, Yuchen Wang, Zhenqi Zhou, Calvin Pan, Ling Jiang, Zhiqiang Zhou, Yonghong Meng, S. Charugundla, Tao Li, H. Allayee, M. Seldin, A. Lusis   +11 more
semanticscholar   +1 more source

Factor XI activity and factor XI antigen in homozygous and heterozygous factor XI deficiency [PDF]

Blood, 1976
A relatively potent antiserum against highly purified, unactivated human factor XI antigen was raised in a rabbit. This antiserum, after concentration, neutralized 50% of the factor XI clotting activity of a standard normal plasma at an antiserum dilution of 1/900.
A, Rimon, S, Schiffman, D I, Feinstein, S I, Rapaport   +3 more
openaire   +3 more sources

Antithrombotic Effects of the Novel Small-Molecule Factor XIa Inhibitor Milvexian in a Rabbit Arteriovenous Shunt Model of Venous Thrombosis

TH Open, 2023
Background Factor XIa (FXIa) is an emerging therapeutic target, and FXIa inhibition is a promising mechanism to improve therapeutic index over current anticoagulants. Milvexian (BMS-986177/JNJ-70033093) is an oral small-molecule FXIa inhibitor.
Xinkang Wang, Qiu Li, Fuyong Du, Neetu Shukla, Andrea R. Nawrocki, Madhu Chintala   +5 more
doaj   +1 more source

Factor XI Inhibition to Uncouple Thrombosis From Hemostasis

Journal of the American College of Cardiology, 2021
Hemostasis and thrombosis are believed to be so intricately linked that any strategies that reduce thrombosis will have an inevitable impact on hemostasis. Consequently, bleeding is viewed as an unavoidable side effect of anticoagulant therapy.
Charles Hsu, E. Hutt, D. Bloomfield, D. Gailani, J. Weitz   +4 more
semanticscholar   +1 more source

A new strategy for anticoagulation: The factor XI inhibitors.

European journal of internal medicine, 2023
Direct oral anticoagulants (DOACs) are currently the first-choice therapy for the prevention of cardioembolic events in patients with atrial fibrillation and for the treatment of venous thromboembolism (VTE) due to their more favorable efficacy to safety
M. Vedovati, C. Becattini, G. Agnelli
semanticscholar   +1 more source

Reducing Plasma Factor XI Concentration With siRNA Technology [PDF]

JACC: Basic to Translational Science
David Gailani, MD
doaj   +2 more sources

The new in anticoagulation: factor XI inhibitors

European Heart Journal, Supplement, 2023
Haemostasis and thrombosis are closely linked, so that any anticoagulant strategy available today that reduces the thrombotic risk inevitably increases the bleeding risk.
Francesca Muscente, R. de Caterina
semanticscholar   +1 more source

Factor XI as a Target for New Anticoagulants

Hämostaseologie, 2021
Despite advances in anticoagulant therapy, thrombosis remains the leading cause of morbidity and mortality worldwide. Heparin and vitamin K antagonists (VKAs), the first anticoagulants to be used successfully for the prevention and treatment of ...
J. Fredenburgh, J. Weitz
semanticscholar   +1 more source

Pharmacokinetics, pharmacodynamics and safety of BAY 2433334, a novel activated factor XI inhibitor, in healthy volunteers: A randomized phase 1 multiple‐dose study

British Journal of Clinical Pharmacology, 2022
To evaluate BAY 2433334, an oral activated factor XI (FXIa) inhibitor, in volunteers.
D. Kubitza, Michael Heckmann, J. Distler, A. Koechel, S. Schwers, F. Kanefendt   +5 more
semanticscholar   +1 more source

Pharmacokinetics and pharmacodynamics of Abelacimab (MAA868), a novel dual inhibitor of Factor XI and Factor XIa

Journal of Thrombosis and Haemostasis, 2021
Factor XI (FXI) inhibition offers the promise of hemostasis‐sparing anticoagulation for the prevention and treatment of thromboembolic events. Abelacimab (MAA868) is a novel fully human monoclonal antibody that targets the catalytic domain and has dual ...
B. Yi, D. Freedholm, Nancy Widener, Xiaohui Wang, Émilie Simard, C. Cullen, N. Al-Saady, N. Lepor, S. Coulter, M. Lovern, D. Bloomfield   +10 more
semanticscholar   +1 more source